A s experience with new anticoagulants is gained, insights on alternative dosing approaches in selected populations become apparent. In this issue, HOffman et al.' present a research report describing post-cardiopulmonary bypass graft (CAB G) patients from a single institution who received the direct thrombin inhibitor (DTI) argatroban in the setting of heparin-inducedthrombocytopenia (HIT). An important observation from their experience is that this population apparently requires a dose much lower than that noted in the clinical trials to achieve a similar level of anticoagulation. However, their observations show that even with a reduced dose at 0.5 jlglkg/min, large variability could still exist, suggesting a continued need to closely monitor and adjust dosing. As the authors note, lower mean argatroban doses ranging from 0.06 to 0.29 jig/kglmin have been re-Ported in critically ill patients with impaired organ function. In their patients who required renal replacement therapy, the median dose was 0.3 jig/kg/min. 1 How, then, should we approach dosing argatroban or other agents with narrow therapeutic windows in this setting, especially shortly after surgery and while still in the intensive care unit?
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wwwsheannalscom observed in a case report of 3 critically ill patients by Reichert et al.,' where initial aPTT values within the target range were subsequently above the target a short time later. Periods of withholding anticoagulant therapy lasting 12 and 26 hours were necessary in 2 patients to lower the aPTT to the target range.
In the analysis by Hoffman et aI., the effects of decreased cardiac output, excess postoperative fluid, and hepatic congestion on dosing could not be determined. Of the 39 patients, valve annuloplasty or replacement occurred in only 10, of whom 9 were in the confirmed HIT cohort. A higher incidence of elevated liver function test results and lower final doses of argatroban were observed in this cohort compared with what appears to be the healthier suspected HIT or previous HIT cohorts. The median timing for initiation of argatroban, however, was 6 days after surgery for confirmed HIT, compared with 2-2.5 days in the smaller, antibody-negative, or suspected HIT cohorts. Once dosing was stabilized, it was unclear whether a difference between the mean aPTf in the subgroups was present. Because of the small sample size, any potential dose-response relationship could not be addressed if argatroban was started within 1-2 days postoperatively.
One strategy to consider when concern for thrombosis is low (eg, isolated HIT) but notable bleeding is high is to initiate the OTIat a lower dose. An aPTT can be measured within 3-4 hours and the infusion rate adjusted to increase the aPTf to the target range if low, limiting the potential for high values and bleeding complications. If the aPTf is within the target range at the reduced dose, overshooting the target may have been avoided ( Figure I ). As cardiac function or organ systems recover, additional dosing adjustments may be necessary. aPTT ratio Infusion rate increase
Identifying Presence of HIT
Presence of a 50% drop in the platelet count early after surgery and delays in HIT antibody testing create a clinical dilemma for decisions to initiate therapy. Positive antibodies by enzyme-linked immunosorbance assay are more common than those detected by serotonin release assay.' Although the clinical suspicion of HIT is higher after a latent drop in the platelet count 5 or more days postoperatively, other causes of thrombocytopenia may be present,s A higher incidence of HIT-related thrombosis may also occur when therapy is delayed until the presence of antibody is confirmed," In one recent analysis of HIT associated with CABG, postoperative platelet transfusions resulted in a higher risk for thrombosis, suggesting a need to recognize and consider alternative anticoagulant strategies to reduce morbidity and mortality.' With the unavailability of aprotinin, use of recombinant activated factor VII, which has also been associated with thrombosis, may lead to postoperative thrombosis concurrent with the lower platelet count." However, presence of pathogenic HIT and approaches to confirm the diagnosis early in the postoperative period after CABG remain controversial.
Separating cohorts by presence of HIT antibody creates difficulties in unmasking other factors influencing a response. Currently, there is no evidence supporting presence of antibody as an independent dose-response factor. In a recent analysis, presence of HIT antibody prior to surgery was associated with postoperative adverse effects and longer length of stay," Hoffman et al. did not undertake a pretest probability assessment to determine the presence of acute HIT. Three of 4 criteria for the 4T pretest probability score described by Warkentin were used to determine Whether clinical HIT was present." The fourth criterion, thrombosis related to HIT, may be difficult to determine retrospectively. One consideration in any retrospective analysis to identify acute HIT is to use a posttest clinical score that incorporates presence of antibody, platelet count recovery, and recurrent thrombocytopenia if rechallenged with heparin.I':" Critically ill patients frequently have other reasons to be thrombocytopenic, limiting the diagnostic value of platelet count recovery and decisions concerning when to initiate warfarin in such patients. 
EXTRAcro
Los cambios fisiol6gicosagudos despues de una cirugfade injerto de derivaci6n pueden resultar temporalmente en una disminuci6nen la eliminaci6n de farmacos y en los requisitos de dosificaci6n paraalcanzarel efecto deseado. Puede que se tengan que considerardosis de farmacos tal como el inhibidordirecto de trombina, argatroban,considerablemente mas bajasal iniciarel tratamiento pocodespuesde la cirugfa, si la ventana terapeutica es estrechay si existedeterioro de la funci6n hepatica, renal 0 cardfaca.La manera de enfocar Ia dosis inicial,seguidade ajustesen la velocidadde infusi6n y concesionespara la prolongaci6ndel tiempo necesariopara establecery mantener un valor del tiempo parcial de tromboplastinaactivadadentro del ambito deseado, tambien tiene que considerarel riesgo de complicacionesde trombosis0 hemorragia.La duraci6n de la reducci6nen dosis puede depender de varias variablesy, segun se recuperanlos sistemas,puede que se tenga que ajustar la dosis hacia arriba. EI analisisretrospectivopara identificartrombocitopenia inducida por heparina puede ser diffcilen situacionesdonde otras causas de trombocitopenia estanpresentes, sugiriendo que tarnbien se consideren los metodosde puntuaei6n despues de Iapruehaparaconfirmarla presencia de trombocitopenia bastaque mejores metodos validados estendisponibles. 
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